Clinical trial
Australian Trial in Acute Hepatitis C
NCT00192569 · Kirby Institute, Other · Completed
Key facts
| NCT number | NCT00192569 |
|---|---|
| Title | Australian Trial in Acute Hepatitis C |
| Official title | Australian Trial in Acute Hepatitis C |
| Lead sponsor | Kirby Institute, Other |
| Collaborators | The University of New South Wales National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Pegylated Interferon alfa 2a, Ribavirin (HIV conifected patients only) |
| Enrollment | 167 |
| Start date | Jul 1, 2004 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 15, 2011 |
| Countries | Australia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: